News

Fierce Pharma56m
FDA rejection of extended dosing interval is another piece of bad news for Regeneron’s Eylea HD
The FDA has sent Regeneron a complete response letter, rejecting its bid to stretch the administration of high-dose Eylea ...
Regeneron Pharmaceuticals, Inc.: Regeneron Provides Update on EYLEA HD (aflibercept) Injection 8 mg Supplemental Biologics License Application
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter ...